EVT-101

From Wikipedia, the free encyclopedia
EVT-101
EVT-101.svg
Clinical data
Other namesENS-101
Drug classNMDA receptor antagonist
Identifiers
  • 5-[3-(Difluoromethyl)-4-fluorophenyl]-3-[(2-methylimidazol-1-yl)methyl]pyridazine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC16H13F3N4
Molar mass318.303 g·mol−1
3D model (JSmol)
  • CC1=NC=CN1CC2=NN=CC(=C2)C3=CC(=C(C=C3)F)C(F)F
  • InChI=1S/C16H13F3N4/c1-10-20-4-5-23(10)9-13-6-12(8-21-22-13)11-2-3-15(17)14(7-11)16(18)19/h2-8,16H,9H2,1H3
  • Key:BOVUHBFXPNLTKF-UHFFFAOYSA-N

EVT-101, also known as ENS-101, is an experimental medication which originated from Roche and is under development by Evotec AG for the treatment of major depressive disorder.[1] It acts as a selective NMDA receptor subunit 2B (NR2B) antagonist.[1][2] As of November 2017, EVT-101 is in phase II clinical trials for major depressive disorder, although no recent reports of development have been identified.[1] The drug was first claimed by Roche in 2002.[3]

See also[edit]

References[edit]

  1. ^ a b c "EVT 101 - AdisInsight".
  2. ^ "Archived copy" (PDF). Archived from the original (PDF) on 2017-08-29. Retrieved 2018-02-10.{{cite web}}: CS1 maint: archived copy as title (link)
  3. ^ Santangelo RM, Acker TM, Zimmerman SS, Katzman BM, Strong KL, Traynelis SF, Liotta DC (2012). "Novel NMDA receptor modulators: an update". Expert Opin Ther Pat. 22 (11): 1337–52. doi:10.1517/13543776.2012.728587. PMC 3677696. PMID 23009122.

External links[edit]